A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers
Targeted Oncology Aug 26, 2017
Escudier B, et al. – Researchers in this study tried to acquire a clinical proof of concept that tasquinimod was active and tolerable in patients with advanced solid tumors. Based on the data obtained, they highlighted the inability of this work to demonstrate clinical activity of tasquinimod in heavily pre–treated patients with advanced hepatocellular, ovarian, renal cell, and gastric cancer.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
